Bisphosphonates in cancer therapy

被引：172

作者：

Stresing, Verena

Daubine, Florence

Benzaid, Ismahene

Moenkkoenen, Hannu

Clezardin, Philippe

机构：

[1] INSERM, Res Unit, U664, Fac Med Laennec, F-69372 Lyon 08, France

[2] Univ Lyon 1, F-69622 Villeurbanne, France

来源：

CANCER LETTERS | 2007年 / 257卷 / 01期

关键词：

bisphosphonate; bone; metastasis; cancer;

D O I：

10.1016/j.canlet.2007.07.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bisphosphonates are the standard of care in the treatment of malignant bone diseases, because of their ability to inhibit osteoclast-mediated bone destruction. We review here preclinical evidence that bisphosphonates also exert direct antitumour effects and antiangiogenic properties. Furthermore, we describe new insights on how bisphosphonates may act synergistically in combination with antineoplastic drugs or gamma delta T cells to exhibit antitumour activity. These findings reveal new exciting possibilities to fully exploit the antitumour potential of bisphosphonates in the clinical practice. (C) 2007 Elsevier Ireland Ltd. All rights reserved.

引用

收藏

页码：16 / 35

页数：20

相关论文

共 143 条

[41] Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival [J].

Gouin, Francois ;

Ory, Benjamin ;

Redini, Francois ;

Heymann, Dominique .

INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (05) :980-984

[42] Recognition of nonpeptide antigens by human Vγ9Vδ2 T cells requires contact with cells of human origin [J].

Green, AE ;

Lissina, A ;

Hutchinson, SL ;

Hewitt, RE ;

Temple, B ;

James, D ;

Boulter, JM ;

Price, DA ;

Sewell, AK .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2004, 136 (03) :472-482

[43] Antitumor effects of bisphosphonates [J].

Green, JR .

CANCER, 2003, 97 (03) :840-847

[44] The hallmarks of cancer [J].

Hanahan, D ;

Weinberg, RA .

CELL, 2000, 100 (01) :57-70

[45]

Hashimoto K, 2005, CANCER RES, V65, P540

[46] Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells [J].

Hashimoto, Kae ;

Morishige, Ken-ichirou ;

Sawada, Kenjiro ;

Tahara, Masahiro ;

Shimizu, Shoko ;

Ogata, Seiji ;

Sakata, Masahiro ;

Tasaka, Keiichi ;

Kimura, Tadashi .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 354 (02) :478-484

[47] Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma [J].

Heymann, D ;

Ory, B ;

Blanchard, F ;

Heymann, MF ;

Coipeau, P ;

Charrier, C ;

Couillaud, S ;

Thiery, JP ;

Gouin, F ;

Redini, F .

BONE, 2005, 37 (01) :74-86

[48] American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer [J].

Hillner, BE ;

Ingle, JN ;

Berenson, JR ;

Janjan, NA ;

Albain, KS ;

Lipton, A ;

Yee, G ;

Biermann, JS ;

Chlebowski, RT ;

Pfister, DG .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (06) :1378-1391

[49] Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model [J].

Hiraga, T ;

Williams, PJ ;

Ueda, A ;

Tamura, D ;

Yoneda, T .

CLINICAL CANCER RESEARCH, 2004, 10 (13) :4559-4567

[50] Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer [J].

Hiraga, T ;

Ueda, A ;

Tamura, D ;

Hata, K ;

Ikeda, F ;

Williams, PJ ;

Yoneda, T .

INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (06) :973-979

← 1 2 3 4 5 6 7 8 9 10 →